Literature DB >> 30227021

Reporting Adverse Drug Reactions in Product Labels.

Brenda Crowe1, Christy Chuang-Stein2, Sally Lettis3, Andreas Brueckner4.   

Abstract

Product labels are intended to provide health care professionals with clear and concise prescribing information that will enhance the safe and effective use of drug products. In this manuscript, we offer suggestions to improve product labels. First, we recommend that product labels that include comparator data be changed to include adjusted incidence proportions (or adjusted incidence rates when needed and appropriate) for adverse drug reactions that are somewhat common. Second, we believe that including comparator incidence in product labels is a good practice, as it gives health care providers and patients appropriate information to put the absolute risks in perspective. Finally, we recommend changing the practice of reporting extremely rare events based on the "Rule of 3" in the Summary of Product Characteristics in Europe. We recommend that these adverse drug reactions be put in a separate table from other adverse drug reactions with a note that it is difficult to reliably estimate their incidences. In exceptional circumstances, it may be possible to present an estimate of their incidence based on postmarketing data. We believe the proposed changes could help product labels to better reflect the risk of a drug relative to a comparator.

Entities:  

Keywords:  adverse drug reactions; adverse events; harms; product label; product safety

Year:  2016        PMID: 30227021     DOI: 10.1177/2168479016628574

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  Neural Multi-Task Learning for Adverse Drug Reaction Extraction.

Authors:  Feifan Liu; Xiaoyu Zheng; Hong Yu; Jennifer Tjia
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

2.  Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis.

Authors:  Benedict Morath; Andreas D Meid; Johannes Rickmann; Jasmin Soethoff; Markus Verch; Matthias Karck; Marcin Zaradzki
Journal:  Drug Saf       Date:  2021-09-26       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.